BioCentury
ARTICLE | Emerging Company Profile

Double threat

How BITT’s TNFR2 mAbs kill tumor cells directly, deplete immunosuppressive Tregs

March 23, 2018 8:15 PM UTC

Boston Immune Technologies & Therapeutics Inc. is developing potentially first-in-class TNFR2 inhibitors that have the dual effect of killing both tumor cells and immunosuppressive Tregs.

President and CEO Russell LaMontagne said tumor necrosis factor receptor 2 (TNFR2; TNFRSF1B) is expressed directly on certain types of tumor cells. “We don’t know the extent or exact percentage, but from our screenings of tissue samples, we think it’s a high percentage of lymphomas, colon, breast and ovarian cancers,” he said. ...